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Abstract
Aims/hypothesis ADAMTS13 is a protease that breaks down
von Willebrand factor (VWF) multimers into smaller, less
active particles. VWF has been associated with an increased
risk of incident type 2 diabetes mellitus. Here, we determine
whether ADAMTS13 activity and VWF antigen are associat-
ed with incident diabetes.
Methods This study included 5176 participants from the
Rotterdam Study, a prospective population-based cohort
study. Participants were free of diabetes at baseline and
followed up for more than 20 years. Cox proportional hazards
models were used to examine the association of ADAMTS13
activity and VWF antigen with incident diabetes.
Results ADAMTS13 activity was associated with an in-
creased risk of incident diabetes (HR 1.17 [95% CI 1.08,
1.27]) after adjustment for known risk factors and VWF anti-
gen levels. Although ADAMTS13 activity was positively as-
sociated with fasting glucose and insulin, the association with
incident diabetes did not change when we adjusted for these
covariates. ADAMTS13 activity was also associated with in-
cident prediabetes (defined on the basis of both fasting and
non-fasting blood glucose) after adjustment for known risk
factors (HR 1.11 [95%CI 1.03, 1.19]), while the VWF antigen
level was not. VWF antigen was associated with incident di-
abetes, but this association was attenuated after adjustment for
known risk factors.
Conclusions/interpretation ADAMTS13 activity appears to
be an independent risk factor for incident prediabetes and type
2 diabetes. As the association between ADAMTS13 and dia-
betes did not appear to be explained by its cleavage of VWF,
ADAMTS13 may have an independent role in the develop-
ment of diabetes.
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Introduction
A disintegrin and metalloprotease with a thrombospondin
type 1 motif, member 13 (ADAMTS13) reduces the activity
of von Willebrand factor (VWF) in platelet adhesion and ag-
gregation by cleaving prothrombotic VWF multimers [1, 2].
Low ADAMTS13 levels and activity are associated with an
increased risk of various thrombotic diseases, including isch-
aemic stroke and myocardial infarction [3–8], as well as kid-
ney disease [9]. Additionally, low ADAMTS13 activity may
contribute to the renal and cardiovascular complications of
diabetes [10–12]. However, the association of ADAMTS13
with diabetes itself remains unexplored. Elevated levels of
VWF have been associated with an increased risk of type 2
diabetes [13–17] which has been attributed primarily to the
role of VWF as a marker of endothelial dysfunction rather
than to its role in thrombosis [18]. However, VWF may also
be associated with diabetes through its prothrombotic effect.
This would be in line with emerging evidence that vascular
disease may contribute to the development of diabetes [19].
Low ADAMTS13 activity and high VWF levels may exacer-
bate small vessel disease, which in turn may contribute to the
development of diabetes [20–22]. If VWF is associated with
diabetes through its prothrombotic function, then we would
expect ADAMTS13, with its antithrombotic function, to be
inversely associated with the risk of diabetes. On the other
hand, little is still known about the regulation of
ADAMTS13 and its role as a marker of other physiological
processes [23]. We previously showed that type 2 diabetes
patients have higher ADAMTS13 activity compared with
controls [8, 23], which is inconsistent with a mechanism in-
volving VWF’s prothrombotic function.
Nevertheless, the association may also reflect a response to
diabetes, and studies on incident diabetes are needed to pro-
vide further insight into the direction of this association. In this
study, we examined whether ADAMTS13 activity or VWF
antigen levels are associated with risk of type 2 diabetes in a
large prospective population-based cohort study.
Methods
Study description and population The Rotterdam Study is a
prospective population-based cohort study initiated in 1990 to
study the determinants of several chronic diseases in older
adults [24]. The first cohort (RS-I) includes 7983 inhabitants
of Ommoord, a district of Rotterdam in the Netherlands, who
were aged ≥55 years at recruitment. The first examination
took place between 1990 and 1993. The third visit, including
4797 participants, took place between March 1997 and
December 1999, and was used as the baseline in this study.
The second cohort (RS-II), established between February
2000 and December 2001, includes another 3011 inhabitants
of Ommoord who either reached the age of 55 years after the
recruitment phase of RS-I or had migrated into the research
area. There were no eligibility criteria to enter the Rotterdam
Study except for age and residential area (postal code). The
Rotterdam Study was approved by the Medical Ethics
Committee of the Erasmus Medical Center and the Ministry
of Health, Welfare and Sport of the Netherlands, through
implementing the Wet Bevolkingsonderzoek: ERGO
(Population Studies Act: Rotterdam Study). All participants
provided written informed consent to participate in the study
and to obtain information from their treating physicians.
Ascertainment of prediabetes and diabetes Diabetes, predi-
abetes and normoglycaemia were defined according to the
most recent WHO guidelines [25]. Prediabetes was defined
as a fasting blood glucose level between 6.0 mmol/l and
7.0 mmol/l or a non-fasting blood glucose level between
7.7 mmol/l and 11.1 mmol/l (when fasting samples were not
available); diabetes was defined as a fasting blood glucose
level of >7.0 mmol/l, a non-fasting blood glucose level of
≥11.1 mmol/l (when fasting samples were not available), or
the use of glucose-lowering medication. Prevalent and inci-
dent diabetes and prediabetes were ascertained using general
practitioner records, hospital discharge letters, pharmacy re-
cords, home interviews and fasting glucose measurements
performed at our research centre during baseline and follow-
up visits [26]. Information regarding the use of blood glucose
lowering medication was derived from both home interviews
and pharmacy records [26]. A schematic representation of the
follow-up design is provided in electronic supplementary ma-
terial (ESM) Fig. 1. At baseline more than 99% of the
Rotterdam Study population was covered by the pharmacies
in the study area. All potential prediabetes and diabetes events
were independently adjudicated by two study physicians; in
the case of disagreement, consensus was sought with the help
of an endocrinologist. Follow-up data is complete until 1
January 2012. Flowcharts detailing the reasons for classifying
prevalent cases of diabetes and prediabetes are shown in ESM
Figs 2 and 3, respectively.
ADAMTS13 activity and VWF antigen measurements
Citrated plasma samples were collected at the third visit of
RS-I and at the baseline examination of RS-II, and stored at
−80°C. Between June and October 2013, we measured
ADAMTS13 activity using a kinetic assay based on the fluo-
rescence resonance energy transfer substrate VWF73
(FRETS-VWF73) assay [27]. Plasma samples were measured
against a reference curve of serially diluted pooled normal
human plasma defined as having an ADAMTS13 activity of
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1 IU/ml, and we expressed ADAMTS13 activity as a percent-
age of this reference value. The ADAMTS13 activity of 6258
participants was measured: 3791 from RS-I and 2467 from
RS-II.
Between July and October of 2008, VWF antigen levels (in
IU/ml) were determined with an in-house ELISA using poly-
clonal rabbit anti-human VWF antibodies (DakoCytomation,
Glostrop, Denmark) for capturing and tagging [28]. The intra-
assay CV was 5.8% and the interassay CV was 7.8%. VWF
antigen levels were measured in 3968 individuals from RS-I
and in 2561 individuals from RS-II.
In total, 5176 participants with VWF and ADAMTS13
measurements also had a fasting glucose measurement and
were free of diabetes at baseline, while 4232 participants were
free of prediabetes at baseline (ESM Fig. 2 and 3).
Covariates BMI was calculated by dividing the weight in kg
by the height in metres squared. Information on current tobacco
smoking was acquired from questionnaires. Lipid-lowering
(statins, fibrates, and other lipid modifying agents), antihyper-
tensive (diuretics, beta blockers, ACE inhibitors, calcium chan-
nel blockers) and antithrombotic medication use was assessed
during a structured home interview. Blood pressure was mea-
sured twice using an oscillometric device after 5 min of rest,
and the mean value was taken as the final reading. Serum total
cholesterol and HDL-cholesterol levels were determined using
an automated enzymatic method. Blood glucose levels were
measured using the glucose hexokinase method
(Instruchemie, Delfzijl, the Netherlands) [29]. Insulin levels
were determined by metric assay (BioSource Diagnostics,
Camarillo, CA, USA). This assay does not cross-react with
either proinsulin or C-peptide. Serum alanine aminotransferase
(ALT) levels were measured using a Merck Diagnostica kit
(Whitehouse Station, NJ, USA) on an Elan Autoanalyzer
(Merck). White blood cell counts were assessed in citrate plas-
ma with a Coulter Counter T540 (Coulter Electronics, Hialeah,
Florida, USA). C-reactive protein (CRP) was measured using
CRPL3, an immunoturbidimetric assay (Roche Diagnostics,
Indianapolis, IN, USA). Prevalent CHD was defined as having
a history of myocardial infarction or coronary revascularisation
procedures, as previously described [30].
Statistical analysis Statistical analyses were performed using
IBM SPSS Statistics software (version 21.0, Armonk, NY,
USA) and R (version 3.1.3; R Foundation for Statistical
Computing, Vienna, Austria). Missing values for covariates
(<5%) were imputed in SPSS using single imputation based
on expectation maximisation. VWF antigen, HDL-cholester-
ol, CRP, ALTand fasting insulin levels were natural log trans-
formed. We used linear regression models to test the associa-
tion of ADAMTS13 activity and VWF antigen level with
fasting glucose and fasting insulin levels. Individuals with
prevalent diabetes were excluded from all analyses.
The association of ADAMTS13 activity and VWF antigen
with incident diabetes was examined using Cox proportional
hazards models. Three adjustment models were used:
Model 1 was adjusted for age, sex and cohort; Model 2
was additionally adjusted for HDL and total cholesterol,
lipid-lowering medication, BMI, CRP, current smoking,
antithrombotic medication, ALT, white blood cell count,
systolic BP, antihypertensive medication and prevalent
CHD; and Model 3 was additionally adjusted for fasting
glucose and insulin. The assumption of proportional
hazards was met for all models. In Model 1 ADAMTS13
activity and VWF antigen were tested separately, whereas
in Models 2 and 3 the analysis of ADAMTS13 activity was
adjusted for VWF antigen level and vice versa. We
examined the interaction between ADAMTS13 activity
and VWF antigen on incident diabetes using a multiplica-
tive interaction term, and adjusting for age, sex and cohort.
Results are shown per SD of VWF antigen levels and
ADAMTS13 activity. We also tested the association of
ADAMTS13 activity quartiles with incident diabetes.
To test whether associations with incident diabetes were
driven by participants with prevalent CHD, or users of lipid-
lowering, antihypertensive and antithrombotic medication, we
excluded participants in each of these subgroups in a sensitiv-
ity analysis.
Results
Baseline characteristics are shown in Table 1. In a median
follow-up of 11.2 years (interquartile range 9.8–12.6), 638
of the 5176 participants who were free of diabetes at baseline
developed diabetes (incidence rate 12.4 per 1000 person-
years). As shown in ESM Fig. 4, 36 of these individuals were
diagnosed during follow-up because they started with insulin
treatment, whereas 278 started using oral glucose-lowering
medication. Another 324 participants were diagnosed with
diabetes because of their high fasting glucose levels. Of the
4232 participants without prevalent prediabetes, 862 devel-
oped prediabetes (incidence rate 21.1 per 1000 person-years).
During follow-up, 13 of these individuals started insulin treat-
ment, 118 started taking oral glucose-loweringmedication and
731 were diagnosed with prediabetes based on their fasting
glucose levels (shown in ESM Fig. 5).
Associations of ADAMTS13 activity and VWF antigen
level with incident diabetes are shown in Table 2.
ADAMTS13 activity was associated with a 19% increased
risk of incident diabetes per SD in the age- and sex-adjusted
model (HR 1.19 [95% CI 1.10, 1.30]), and this association
remained unchanged after adjusting for potential confounders.
Participants in the highest quartile of ADAMTS13 activity
had a 46% increased risk compared with participants in the
lowest quartile (HR 1.46 [95% CI 1.15, 1.85]). Increased
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VWF antigen level was associated with a 12% (HR 1.12 [95%
CI 1.03, 1.21]) increased risk of incident diabetes per SD in
the age- and sex-adjusted model. However, the increased risk
was attenuated to 6% (HR 1.06 [95%CI 0.98, 1.15]) increased
risk per SD after adjustment for additional covariates, and was
8% (HR 1.08 [95%CI 0.99, 1.17]) after further adjustment for
fasting glucose and insulin levels.
Both ADAMTS13 activity and VWF antigen level were
positively associated with the baseline fasting insulin level,
and ADAMTS13 activity was positively associated with the
baseline fasting glucose level (ESM Table 1). Nevertheless,
when we additionally adjusted for fasting glucose and insulin
levels, the effect sizes did not change. These associations were
robust to the exclusion of participants with prevalent CHD at
baseline and to the exclusion of users of lipid-lowering, anti-
hypertensive and antithrombotic medications (ESM Table 2).
There was an interaction between ADAMTS13 activity and
VWF antigen level with incident diabetes (p= 0.01). As
shown in Fig. 1, the association of ADAMTS13 activity with
incident diabetes was strongest in the fourth quartile of VWF
antigen level (HR 1.49 [95% CI 1.27, 1.75]).
Furthermore, ADAMTS13 activity was also associated
with an 11% (HR 1.11 [95% CI 1.03, 1.19]) increased risk
of prediabetes per SD in Model 1, and this association was
similar in Models 2 and 3 (Fig. 2). In contrast, VWF antigen
level was not associated with incident prediabetes.
Discussion
In our study, ADAMTS13 activity was associated with an
increased risk of incident diabetes, even after adjustment for
other known risk factors, including VWF antigen, fasting glu-
cose and fasting insulin levels. Furthermore, ADAMTS13 ac-
tivity was associated with the incidence of prediabetes among
participants with normoglycaemia at baseline. The VWF an-
tigen level was also associated with an increased risk of dia-
betes, but this association was attenuated after adjustment for
known risk factors. These results suggest a role for
ADAMTS13 in the occurrence of type 2 diabetes at an early
stage before glucose levels rise.
To our knowledge, the association of ADAMTS13 with
diabetes has not previously been studied with diabetes used
as the primary outcome, and we are the first to examine this
association in a large prospective population-based cohort
study. One cross-sectional study reported an association be-
tween ADAMTS13 and prevalent diabetes [12]. These
Table 2 HRs for ADAMTS13 activity on incident type 2 diabetes
ADAMTS13 activity Model 1 Model 2 Model 3
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Continuous (per SD) 1.19 (1.10, 1.30) 0.00003 1.17 (1.08, 1.27) 0.0001 1.17 (1.08, 1.27) 0.00009
Quartile 1 (Ncases: 129) Reference Reference Reference
Quartile 2 (Ncases: 150) 1.12 (0.88, 1.42) 0.4 1.10 (0.87, 1.39) 0.4 1.12 (0.88, 1.41) 0.4
Quartile 3 (Ncases: 168) 1.26 (1.00, 1.59) 0.05 1.31 (1.03, 1.65) 0.03 1.36 (1.08, 1.73) 0.01
Quartile 4 (Ncases: 191) 1.47 (1.16, 1.86) 0.001 1.46 (1.15, 1.85) 0.002 1.48 (1.17, 1.88) 0.001
Model 1 was adjusted for age, sex and cohort; Model 2 was additionally adjusted for VWF antigen, HDL and total cholesterol, lipid-lowering
medication, body-mass index, CRP, former smoking, current smoking, antithrombotic medication, ALT, white blood cell count, systolic BP, antihyper-
tensive medication and prevalent CHD; and Model 3 was additionally adjusted for glucose and insulin levels
HDL-cholesterol, CRP, ALT and insulin were natural log transformed before use
Ncases, number of incident diabetes cases
Table 1 Baseline characteristics of the study population
Characteristic Value
Age (years) 69.0 ± 8.1
Sex (female) 57.7
BMI (kg/m2) 26.7 ± 3.8
HDL-cholesterol (mmol/l) 1.3 (1.12–1.60)
Total cholesterol (mmol/l) 5.9 ± 1.0
Lipid-lowering medication use 11.4
Systolic BP (mmHg) 142.1 ± 21.0
Antihypertensive medication use 20.8
ALT (U/l) 20.0 (16.0–26.0)
Former smoker 40.7
Current smoker 12.5
CRP (nmol/l) 21.0 (10.0–44.3)
White blood cell count (×109 cells/l) 6.7 ± 1.9
Prevalent CHD 7.3
Prevalent prediabetes 18.2
Fasting glucose level (mmol/l) 5.5 ± 0.5
Fasting insulin level (pmol/l) 71.36 (50.60–100.00)
Antithrombotic medication use 17.4
ADAMTS13 activity (%) 91.0 ± 17.2
VWF antigen level (IU/ml) 1.3 ± 0.6
N= 5176
Data are the mean± SD, percentage or median (interquartile range)
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researchers did not observe a significant difference in
ADAMTS13 levels between 86 diabetes patients and 26
healthy controls. We previously observed that ADAMTS13
activity is 5% higher in participants with prevalent diabetes
compared with those without prevalent diabetes [31]. In the
current study, we excluded participants with prevalent diabe-
tes, and instead focused on the risk of future diabetes. The
results of this study are therefore largely independent of the
results of the previous cross-sectional study.
Our results for VWF are consistent with those of previous
studies. VWF has been associated with incident diabetes in a
range of studies [13–17], but in general the association weak-
ened after adjustment for confounders and became non-signif-
icant. In the Framingham Heart Study, however, VWF
remained significantly associated with incident diabetes after
adjustment for a wide range of potential confounders, includ-
ing insulin resistance [14]. Similarly, in the Coronary Artery
Risk Development in Young Adults study, VWF remained
associated with insulin resistance after multivariable adjust-
ment [32]. VWF is a marker of endothelial dysfunction, which
is thought to explain the association between VWF levels and
diabetes [18]. We report an interaction between ADAMTS13
activity and VWF, with the largest effect of ADAMTS13 ac-
tivity in participants within the highest quartile of VWF levels.
This interaction suggests that the effect of ADAMTS13 is
mainly present in individuals with advanced endothelial
dysfunction.
The mechanism underlying the association of ADAMTS13
activity with diabetes remains unclear. The findings that the
association was robust to the adjustment for baseline fasting
glucose and insulin levels and that ADAMTS13 activity was
also associated with incident prediabetes limit the possibility
of reverse causation. The latter association, for example, sug-
gests that high ADAMTS13 activity in individuals with
healthy glucose metabolism is associated with development
of the early subclinical stages of type 2 diabetes. However, the
association between ADAMTS13 activity and diabetes is un-
likely to be explained by its only robustly identified function
as a cleaving protease of VWF, because in that case we would
expect VWF level (prothrombotic) and ADAMTS13 activity
(antithrombotic) to be associated with diabetes in opposite
directions. An alternative hypothesis is that ADAMTS13 has
an additional proteolytic functionality beyond VWF cleavage.
After an initial interaction with globular VWF, ADAMTS13
undergoes a conformational change that increases its ability to
break down VWF [33]. Recent research suggests that this
conformational change increases the ability of ADAMTS13
to break down not only VWF but also other proteins such as
fibrinogen [34]. ADAMTS13 activity, as measured in our
study, may partly reflect this process. As such, the observed
association between ADAMTS13 activity and incident type 2
diabetesmight be explained by the interaction of ADAMTS13
with one or more currently unknown proteins. Finally, the
association could be explained by pathways responding to
ADAMTS13. For example, there is preliminary evidence that
ADAMTS13 upregulates vascular endothelial growth factor, a
protein involved in angiogenesis that may contribute to the
development of type 2 diabetes [35, 36]. ADAMTS13 may
similarly activate other pathways that lead to the development
of type 2 diabetes. However, since its discovery in 2001, most
ADAMTS13 research has focused on its interactions with
VWF and its role in thrombotic thrombocytopenic purpura.
Therefore, we believe that further research is required to elu-
cidate other pathways affected by ADAMTS13.
ADAMTS13 activity
Model 1
Model 2
Model 3
Model 1
Model 2
Model 3
0.9 1.0 1.1
HR
1.2 1.3
VWF antigen
Fig. 2 HRs of ADAMTS13
activity and natural log
transformed VWF antigen (per
SD) for incident prediabetes,
excluding participants with
prediabetes at baseline (862
events in 4232 participants).
Horizontal bars represent 95%
CIs
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Fig. 1 HRs of ADAMTS13 activity (per SD) for incident type 2 diabetes
across quartiles of VWF antigen: interaction between ADAMTS13 and
VWF. Vertical bars represent 95% CIs
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We measured ADAMTS13 activity using the FRETS-
VWF73 assay, which is based on a synthetic peptide spanning
the VWF cleavage site [27]. An alternative is to measure
ADAMTS13 antigen levels, which correspond to the abun-
dance of ADAMTS13. Future studies should investigate
whether ADAMTS13 activity or antigen level is most strongly
associated with diabetes. If the association with diabetes is
strongest with ADAMTS13 antigen, then the association of
markers of ADAMTS13 gene expression and of ADAMTS13
synthesis, secretion and degradation with diabetes should be
explored. Alternatively, a stronger association with
ADAMTS13 activity implicates a factor downstream of
VWF cleavage and not decreased VWF activity itself.
The strengths of our study include the comprehensive as-
sessment of incident diabetes and prediabetes using medical
records, links with pharmacies in the study area and
standardised blood glucose measurement at each follow-up
visit. Additionally, we used data from a well-characterised
prospective population-based cohort study, which enabled us
to correct for a wide range of covariates. We used a long
follow-up and adjusted for baseline fasting glucose and insu-
lin levels to reduce the possibility of reverse causation. By also
examining associations with incident prediabetes, we provide
insight into the early development of subclinical disease.
The main limitation of our study is that, as for all observa-
tional studies, we cannot rule out residual confounding. In
addition, we included individuals aged ≥55 years and effect
estimates might not be generalisable to younger individuals.
Another limitation of this study is that we did not measure
VWF activity or the ratio of small inactive VWF to large
active VWF. Such measurements would provide insight into
whether the observed association is related to the proteolysis
of VWF by ADAMTS13.
In conclusion, we identified ADAMTS13 activity as a nov-
el independent marker of incident diabetes that is associated
with both diabetes and prediabetes. Further research is neces-
sary to confirm this association and to elucidate the biological
mechanism underlying this association. Exploration of alter-
native mechanisms of ADAMTS13 beyond VWF cleavage is
warranted because the association may not be explained by its
antithrombotic function.
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